secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2023-03-08T23:59:59+00:00
Accession:  0001628280-23-006972
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex Q4 revenue $21.0M (+18% YoY), Adj EBITDA turns positive at $0.4M
--------------------------------------------------------------------------

- Q4 net sales $21.0M (+18% YoY); Tru Niagen sales $16.1M (+14% YoY).
- Net loss narrowed to $1.4M ($0.02 loss per share) from $5.3M loss a year ago.
- Adjusted EBITDA profit $0.4M, a $3.8M improvement vs Q4 2021 loss.
- Full year net sales $72.0M (+7%); net loss $16.5M, improved $6.6M YoY.
- Signed long-term supply deal with Nestlé Health Science; entered China via Sinopharm Xingsha.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828023006972/0001628280-23-006972-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828023006972/cdxc-20230308.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-006972

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer